Embryonic stem cells could help to overcome immune rejection problems

Apr 11, 2008

Tissues derived from embryonic stem (ES) cells could help to pacify the immune system and so prevent recipients from rejecting them, the UK National Stem Cell Network Science Meeting will hear today. Speaking at the conference in Edinburgh, Dr Paul Fairchild from the University of Oxford will tell delegates that although tissues derived from ES cells succumb to rejection, they have an inherent immune-privilege which, if exploited, could have far reaching implications for the treatment of conditions such as diabetes, heart attacks and Parkinson’s.

The exciting potential of ES cells for use in regenerative medicine may only be realised by better understanding of how to manage the body’s immune response to them. With funding from the Medical Research Council, Dr Fairchild and Dr Nathan Robertson are investigating whether tissues derived from ES cells will be rejected in the conventional manner or whether the recipients will not recognise them as foreign.

So far, their findings suggest that, while ES cells are fully susceptible to rejection, they do display some underlying immune privilege which, with better understanding, could be harnessed to promote the activity of regulatory T-cells to suppress activation of the immune system.

Dr Paul Fairchild, explains: “Our work provides hope that the immune system may be persuaded to accept tissues derived from ES cells more readily than has been the case for tissues and organs from conventional sources. It appears that ES cell-derived tissues contribute to their own acceptance by creating an environment conducive to T cell regulation, which may one day be harnessed therapeutically.”

The Oxford team generated a panel of ES cell lines from strains of mice that differed from recipients by increasing levels of genetic disparity and used them as a source of tissues for transplantation. Their results show that while minor differences between the two strains provoke prompt rejection in the absence of immune suppression, ES cells do show an underlying tendency for immune privilege.

The next stage of the team’s work is to explore further the molecular and cellular basis of this immune-privilege, whether it might be augmented therapeutically and whether unwanted viruses or tumours could exploit ES cell-derived tissues as a safe-haven where they can evade the normal immune response.

Source: Biotechnology and Biological Sciences Research Council

Explore further: Scientists describe the function of an enzyme critical to male fertility

add to favorites email to friend print save as pdf

Related Stories

The super-resolution revolution

Feb 27, 2015

Cambridge scientists are part of a resolution revolution. Building powerful instruments that shatter the physical limits of optical microscopy, they are beginning to watch molecular processes as they happen, ...

Retracing the roots of fungal symbioses

Feb 23, 2015

With apologies to the poet John Donne, and based on recent work from the U.S. Department of Energy Joint Genome Institute (DOE JGI), a DOE Office of Science user facility, it can be said that no plant is ...

Golden vehicle for drug delivery has hidden costs

Feb 18, 2015

One of the biggest ideas in treating disease involves material so small it isn't even visible. Miniscule gold particles – the size of several atoms – are being touted as vehicles to send drugs exactly ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.